Inventor · disambiguated record
Felix Gonzalez Lopez De Turiso
Also filed as: GONZALEZ LOPEZ DE TURISO FELIX
23 granted patents·19 pending applications·88 citations·filing 2008–2023
94Inventor score
Top patents by PatentIndex Score
42 records- 0196US11299479B1Bisamide sarcomere activating compounds and uses thereofAMGEN INC·Filed 2020·Granted Apr 12, 2022·8 cites·23 claims
- 0296US10899746B2Bisamide sarcomere activating compounds and uses thereofAMGEN INC·Filed 2020·Granted Jan 26, 2021·5 cites·27 claims
- 0394US11780826B2Bisamide sarcomere activating compounds and uses thereofAMGEN INC·Filed 2022·Granted Oct 10, 2023·2 cites·19 claims
- 0491US8586739B2Heterocyclic compounds and their usesCHEN YI·Filed 2012·Granted Nov 19, 2013·13 cites·7 claims
- 0588US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 0688US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 0787US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 0886US9376425B2Heterocyclic compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2012·Granted Jun 28, 2016·12 cites·37 claims
- 0983US2024158372A1Bisamide sarcomere activating compounds and uses thereofAMGEN INC·Filed 2023·Application pending·0 cites
- 1082US8940724B2Quinoline derivitives and their usesCUSHING TIMOTHY D·Filed 2010·Granted Jan 27, 2015·14 cites·8 claims
- 1182US8716290B2Heterocyclic compounds and their usesAMGEN INC·Filed 2013·Granted May 6, 2014·5 cites·15 claims
- 1281US11306107B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2017·Granted Apr 19, 2022·2 cites·11 claims
- 1380US11814362B2ASK1 inhibiting agentsBIOGEN MA INC·Filed 2019·Granted Nov 14, 2023·1 cites·16 claims
- 1480US8901135B2Heterocyclic compounds and their usesCHEN YI·Filed 2012·Granted Dec 2, 2014·3 cites·16 claims
- 1580US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 1679US8633313B2Heterocyclic compounds and their usesCUSHING TIMOTHY DAVID·Filed 2010·Granted Jan 21, 2014·5 cites·8 claims
- 1778US8765940B2Heterocyclic compounds and their usesBROWN MATTHEW·Filed 2010·Granted Jul 1, 2014·5 cites·5 claims
- 1874US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 1973US12404263B2ASK1 inhibiting agentsBIOGEN MA INC·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 2073US9873701B2Heterocyclic compounds and their usesAMGEN INC·Filed 2014·Granted Jan 23, 2018·1 cites·16 claims
- 2167US2020048265A1Heterocyclic compounds and their usesAMGEN INC·Filed 2019·Application pending·0 cites
- 2267US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 2365US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 2464US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 2563US2018105532A1Heterocyclic compounds and their usesAMGEN INC·Filed 2017·Application pending·0 cites
- 2660US2025152574A1Emopamil-binding protein inhibitors and uses thereofBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 2760US2025171463A1Emopamil-binding protein inhibitors and uses thereofBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 2860US2025161281A1Emopamil-binding protein inhibitors and uses thereofBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 2956US8765788B2Tricyclic inhibitors of hydroxysteroid dehydrogenasesPOWERS JAY P·Filed 2008·Granted Jul 1, 2014·0 cites·4 claims
- 3053US8835432B2Heterocyclic compounds and their usesAMGEN INC·Filed 2014·Granted Sep 16, 2014·0 cites·8 claims
- 3152US2024083900A1Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitorsBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 3252US2024327380A1Btk inhibitorsBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 3349US11897898B2Pyridine macrocycle compounds as ASK1 inhibiting agentsBIOGEN MA INC·Filed 2019·Granted Feb 13, 2024·0 cites·21 claims
- 3446US11999715B2ASK1 inhibiting agentsBIOGEN MA INC·Filed 2019·Granted Jun 4, 2024·0 cites·20 claims
- 3546US9873704B2Heterocyclic compounds and their usesAMGEN INC·Filed 2016·Granted Jan 23, 2018·0 cites·3 claims
- 3646US2016002185A1Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Application pending·0 cites
- 3743US11407721B2CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2018·Granted Aug 9, 2022·0 cites·46 claims
- 3843US2010331306A1Heterocyclic compounds and their usesAMGEN INC·Filed 2010·Application pending·0 cites
- 3941US11168095B2ASK1 inhibiting agentsBIOGEN MA INC·Filed 2018·Granted Nov 9, 2021·0 cites·16 claims
- 4039US2013267526A1Heterocyclic compounds and their usesCHEN YI·Filed 2011·Application pending·0 cites
- 4131US2013079342A1Heterocyclic compounds and their usesDRANSFIELD PAUL JOHN·Filed 2011·Application pending·0 cites
- 4231US2013090323A1Heterocyclic compounds and their usesDRANSFIELD PAUL JOHN·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Felix Gonzalez Lopez De Turiso files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →